{"trials":{"trials":[{"nct_id":"NCT05233982","title":"MITO 35a: Olaparib Maintenance Therapy in Newly Diagnosed BRCA Wild-type Advanced Ovarian, Fallopian Tube and Primitive Peritoneal Cancer","status":"RECRUITING","phases":null,"phase":null,"conditions":"[\"gynecologic_oncology\"]","interventions":["Olaparib Oral Product"],"score":0.0,"match_score":0.0,"keyword_matches":{},"combo_matches":[],"is_tagged":false,"reasoning":{"why_eligible":["Matches Ovarian Cancer query","Status: RECRUITING"],"why_good_fit":["Runtime MoA Confidence: 0.8"],"whats_required":["Review protocol"]},"locations":[],"source_url":"https://clinicaltrials.gov/study/NCT05233982","moa_vector":{"ddr":0.8,"mapk":0.0,"pi3k":0.0,"vegf":0.0,"her2":0.0,"io":0.2,"efflux":0.0},"holistic_score":0.685,"mechanism_fit_score":0.971,"eligibility_score":0.0,"pgx_safety_score":1.0,"holistic_interpretation":"INELIGIBLE","holistic_recommendation":"âŒ INELIGIBLE for NCT05233982: Patient does not meet hard eligibility criteria (recruiting status, age, or other requirements). Consider alternative trials."},{"nct_id":"NCT05255471","title":"MITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients.","status":"RECRUITING","phases":null,"phase":null,"conditions":"[\"gynecologic_oncology\"]","interventions":["Olaparib","Chemotherapy drug"],"score":0.0,"match_score":0.0,"keyword_matches":{},"combo_matches":[],"is_tagged":false,"reasoning":{"why_eligible":["Matches Ovarian Cancer query","Status: RECRUITING"],"why_good_fit":["Runtime MoA Confidence: 0.8"],"whats_required":["Review protocol"]},"locations":[],"source_url":"https://clinicaltrials.gov/study/NCT05255471","moa_vector":{"ddr":0.8,"mapk":0.0,"pi3k":0.0,"vegf":0.0,"her2":0.0,"io":0.2,"efflux":0.0},"holistic_score":0.685,"mechanism_fit_score":0.971,"eligibility_score":0.0,"pgx_safety_score":1.0,"holistic_interpretation":"INELIGIBLE","holistic_recommendation":"âŒ INELIGIBLE for NCT05255471: Patient does not meet hard eligibility criteria (recruiting status, age, or other requirements). Consider alternative trials."},{"nct_id":"NCT03878849","title":"Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer","status":"RECRUITING","phases":null,"phase":null,"conditions":"[\"gynecologic_oncology\"]","interventions":["2X-121","2X-121"],"score":0.0,"match_score":0.0,"keyword_matches":{},"combo_matches":[],"is_tagged":false,"reasoning":{"why_eligible":["Matches Ovarian Cancer query","Status: RECRUITING"],"why_good_fit":["Runtime MoA Confidence: 0.7"],"whats_required":["Review protocol"]},"locations":[{"facility":"OU Health Stephenson Cancer","city":"Oklahoma City","state":"Oklahoma","zip":"73104","country":"United States","status":"RECRUITING","contact_name":"Christine Pappaterra","contact_phone":"405-271-8707","contact_email":"Christine-Pappaterra@ouhsc.edu"},{"facility":"Swedish Center for Research and Innovation","city":"Seattle","state":"Washington","zip":"98122","country":"United States","status":"RECRUITING","contact_name":"Karina Sills","contact_phone":"1.206.386.2227","contact_email":"karina.sills@swedish.org"}],"source_url":"https://clinicaltrials.gov/study/NCT03878849","moa_vector":{"ddr":0.8,"mapk":0.0,"pi3k":0.0,"vegf":0.0,"her2":0.0,"io":0.2,"efflux":0.0},"holistic_score":0.685,"mechanism_fit_score":0.971,"eligibility_score":0.0,"pgx_safety_score":1.0,"holistic_interpretation":"INELIGIBLE","holistic_recommendation":"âŒ INELIGIBLE for NCT03878849: Patient does not meet hard eligibility criteria (recruiting status, age, or other requirements). Consider alternative trials."},{"nct_id":"NCT06234423","title":"A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors","status":"RECRUITING","phases":null,"phase":null,"conditions":"[\"gynecologic_oncology\"]","interventions":["CUSP06"],"score":0.0,"match_score":0.0,"keyword_matches":{},"combo_matches":[],"is_tagged":false,"reasoning":{"why_eligible":["Matches Ovarian Cancer query","Status: RECRUITING"],"why_good_fit":["Runtime MoA Confidence: 0.7"],"whats_required":["Review protocol"]},"locations":[{"facility":"Sarah Cannon Research Institute at HealthONE","city":"Denver","state":"Colorado","zip":"80218","country":"United States","status":"RECRUITING","contact_name":"Gerald Falchook, MD, MS","contact_phone":"","contact_email":""},{"facility":"Yale University","city":"New Haven","state":"Connecticut","zip":"06520","country":"United States","status":"RECRUITING","contact_name":"Patricia LoRusso, DO","contact_phone":"","contact_email":""},{"facility":"Florida Cancer Specialists","city":"Sarasota","state":"Florida","zip":"34232","country":"United States","status":"RECRUITING","contact_name":"Manish Patel, MD","contact_phone":"","contact_email":""},{"facility":"Dana Farber Cancer Institute","city":"Boston","state":"Massachusetts","zip":"02115","country":"United States","status":"RECRUITING","contact_name":"Elizabeth K Lee, MD","contact_phone":"","contact_email":""},{"facility":"NYU Cancer Institute Clinical Cancer Center","city":"New York","state":"New York","zip":"10016","country":"United States","status":"RECRUITING","contact_name":"Bhavana Pothuri, M.D.","contact_phone":"","contact_email":""},{"facility":"Memorial Sloan Kettering Cancer Center","city":"New York","state":"New York","zip":"10021","country":"United States","status":"RECRUITING","contact_name":"Roisin O'Cearbhaill, MD","contact_phone":"","contact_email":""},{"facility":"Stephenson Cancer Center","city":"Oklahoma City","state":"Oklahoma","zip":"73104","country":"United States","status":"RECRUITING","contact_name":"Debra Richardson, MD","contact_phone":"","contact_email":""},{"facility":"SCRI Oncology Partners","city":"Nashville","state":"Tennessee","zip":"37203","country":"United States","status":"RECRUITING","contact_name":"Vivek Subbiah, MD","contact_phone":"","contact_email":""},{"facility":"MD Anderson Cancer Center","city":"Houston","state":"Texas","zip":"77030","country":"United States","status":"RECRUITING","contact_name":"Funda Meric-Bernstam, MD","contact_phone":"","contact_email":""},{"facility":"NEXT Oncology","city":"Fairfax","state":"Virginia","zip":"22031","country":"United States","status":"RECRUITING","contact_name":"Alex Spira, MD","contact_phone":"","contact_email":""}],"source_url":"https://clinicaltrials.gov/study/NCT06234423","moa_vector":{"ddr":0.8,"mapk":0.0,"pi3k":0.0,"vegf":0.0,"her2":0.0,"io":0.2,"efflux":0.0},"holistic_score":0.685,"mechanism_fit_score":0.971,"eligibility_score":0.0,"pgx_safety_score":1.0,"holistic_interpretation":"INELIGIBLE","holistic_recommendation":"âŒ INELIGIBLE for NCT06234423: Patient does not meet hard eligibility criteria (recruiting status, age, or other requirements). Consider alternative trials."},{"nct_id":"NCT02101775","title":"Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","status":"ACTIVE_NOT_RECRUITING","phases":null,"phase":null,"conditions":"[\"gynecologic_oncology\"]","interventions":["Adavosertib","Gemcitabine Hydrochloride","Laboratory Biomarker Analysis","Pharmacological Study","Placebo Administration","Questionnaire Administration"],"score":0.0,"match_score":0.0,"keyword_matches":{},"combo_matches":[],"is_tagged":false,"reasoning":{"why_eligible":["Matches Ovarian Cancer query","Status: ACTIVE_NOT_RECRUITING"],"why_good_fit":["Runtime MoA Confidence: 0.8"],"whats_required":["Review protocol"]},"locations":[{"facility":"City of Hope Comprehensive Cancer Center","city":"Duarte","state":"California","zip":"91010","country":"United States","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"City of Hope South Pasadena","city":"South Pasadena","state":"California","zip":"91030","country":"United States","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"University of Chicago Comprehensive Cancer Center","city":"Chicago","state":"Illinois","zip":"60637","country":"United States","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Decatur Memorial Hospital","city":"Decatur","state":"Illinois","zip":"62526","country":"United States","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Indiana University/Melvin and Bren Simon Cancer Center","city":"Indianapolis","state":"Indiana","zip":"46202","country":"United States","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Mayo Clinic in Rochester","city":"Rochester","state":"Minnesota","zip":"55905","country":"United States","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Fox Chase Cancer Center","city":"Philadelphia","state":"Pennsylvania","zip":"19111","country":"United States","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"University of Pittsburgh Cancer Institute (UPCI)","city":"Pittsburgh","state":"Pennsylvania","zip":"15232","country":"United States","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"BCCA-Cancer Centre for the Southern Interior","city":"Kelowna","state":"British Columbia","zip":"V1Y 5L3","country":"Canada","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"BCCA-Vancouver Cancer Centre","city":"Vancouver","state":"British Columbia","zip":"V5Z 4E6","country":"Canada","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"London Regional Cancer Program","city":"London","state":"Ontario","zip":"N6A 4L6","country":"Canada","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Ottawa Hospital and Cancer Center-General Campus","city":"Ottawa","state":"Ontario","zip":"K1H 8L6","country":"Canada","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"University Health Network Princess Margaret Cancer Center P2C","city":"Toronto","state":"Ontario","zip":"M5G 2M9","country":"Canada","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"University Health Network-Princess Margaret Hospital","city":"Toronto","state":"Ontario","zip":"M5G 2M9","country":"Canada","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"CHUM - Centre Hospitalier de l'Universite de Montreal","city":"Montreal","state":"Quebec","zip":"H2X 3E4","country":"Canada","status":"","contact_name":"","contact_phone":"","contact_email":""}],"source_url":"https://clinicaltrials.gov/study/NCT02101775","moa_vector":{"ddr":0.8,"mapk":0.2,"pi3k":0.0,"vegf":0.0,"her2":0.0,"io":0.0,"efflux":0.0},"holistic_score":0.675,"mechanism_fit_score":0.95,"eligibility_score":0.0,"pgx_safety_score":1.0,"holistic_interpretation":"INELIGIBLE","holistic_recommendation":"âŒ INELIGIBLE for NCT02101775: Patient does not meet hard eligibility criteria (recruiting status, age, or other requirements). Consider alternative trials."}],"summary":{"total_found":5,"note":"Intent-gated ranking: 5 therapeutic drug trials aligned to Ayesha's profile (MBD4/BER, TP53, PD-L1+). Non-therapeutic studies excluded.","ranking_method":"intent_gated_ayesha_v1"},"provenance":{}},"soc_recommendation":{"regimen":"Carboplatin AUC 5-6 + Paclitaxel 175 mg/mÂ²","confidence":0.95,"rationale":"NCCN Category 1 for first-line Stage IVB HGSOC","engine_validation":null,"add_ons":[],"evidence":["NCCN Guidelines v2024","GOG-218","ICON7"]},"ca125_intelligence":{"burden_class":"EXTENSIVE","burden_score":0.7775280682546419,"forecast":{"complete_response_target":35,"complete_response_target_unit":"U/mL","note":"Baseline CA-125 not available. General expectations: â‰¥70% drop by cycle 3, â‰¥90% by cycle 6 for chemo-sensitive disease."},"resistance_signals":[],"monitoring_strategy":{"frequency":"every_2_weeks","timing":"Until treatment initiation","rationale":"High baseline; track any changes before treatment","method":"Serum CA-125 (U/mL)"},"clinical_notes":"CA-125 of 2842.0 U/mL indicates EXTENSIVE disease burden (>1,000). CA-125 is highly trackable and suitable for response monitoring. Complete response target: <35 U/mL. Additional therapy cycles likely needed.","provenance":{"method":"ca125_intelligence_v1","data_sources":["GOG-218","ICON7","NCCN Guidelines v2024"],"thresholds":{"MINIMAL":[0,100],"MODERATE":[100,500],"SIGNIFICANT":[500,1000],"EXTENSIVE":[1000,null]},"expectations":{"cycle3_drop_percent":70,"cycle6_drop_percent":90,"complete_response_threshold":35,"resistance_threshold_percent":50},"analyzed_at":"2026-01-31T03:17:49.131975","run_id":"ca125_1769847469"}},"wiwfm":{"status":"awaiting_ngs","message":"Personalized drug efficacy predictions require tumor NGS data (somatic mutations, HRD, TMB, MSI)","ngs_fast_track":{"ctDNA":"Guardant360 - somatic BRCA/HRR, TMB, MSI (7-10 days)","tissue_HRD":"MyChoice - HRD score for PARP maintenance planning (7-14 days)","IHC":"WT1/PAX8/p53 - confirm high-grade serous histology (1-3 days)"},"confidence":null,"note":"Once NGS available, WIWFM will provide Evo2-powered S/P/E drug ranking with 70-85% confidence"},"io_selection":{"eligible":false,"eligibility_signals":[],"eligibility_quality":"insufficient","needs_confirmatory_biomarkers":["tmb","msi_status","mmr_status","pd_l1_cps"],"evidence_gap":"No IO eligibility signals found (need MSI/TMB/PD-L1 or hypermutator evidence).","selected_safest":null,"candidates":[],"ruo_disclaimer":"Research Use Only (RUO). This is decision support, not medical advice.","provenance":{"service":"io_safest_selection_service","version":"v1"}},"food_validation":null,"supplement_recommendations":null,"resistance_playbook":null,"next_test_recommender":{"recommendations":[{"test_name":"HRD Score (MyChoice CDx or tissue-based NGS)","priority":1,"turnaround_days":10,"cost_estimate":"$4,000-$6,000 (typically covered by insurance for Stage III/IV ovarian)","impact_if_positive":"HRD â‰¥42 â†’ PARP maintenance eligible (NCCN Category 1). Unlock mechanism map DDR chip.","impact_if_negative":"HRD <42 â†’ PARP reduced benefit. Consider ATR/CHK1 combo or platinum-only.","rationale":"HRD score determines PARP inhibitor eligibility and confidence level.","urgency":"high","test_type":"tissue","ordering_info":"Order via Myriad Genetics (MyChoice CDx) or comprehensive tumor NGS."},{"test_name":"ctDNA Comprehensive Panel (Guardant360 CDx or FoundationOne Liquid CDx)","priority":2,"turnaround_days":7,"cost_estimate":"$5,000-$7,000 (typically covered by insurance)","impact_if_positive":"MSI-High/TMBâ‰¥20 â†’ IO eligible. Somatic HRR â†’ PARP confidence 90%.","impact_if_negative":"MSI-Stable/TMB<20 â†’ IO lower priority. No somatic HRR â†’ Standard care.","rationale":"MSI/TMB unlock immunotherapy. Somatic HRR mutations enable PARP strategies.","urgency":"high","test_type":"blood","ordering_info":"Order via Guardant Health or Foundation Medicine. 2-3 tubes blood (EDTA)."},{"test_name":"SLFN11 IHC (Immunohistochemistry)","priority":3,"turnaround_days":5,"cost_estimate":"$300-$500","impact_if_positive":"SLFN11+ â†’ Normal PARP sensitivity maintained.","impact_if_negative":"SLFN11- â†’ Reduced PARP sensitivity. Consider ATR/CHK1.","rationale":"SLFN11 expression correlates with PARP inhibitor response.","urgency":"medium","test_type":"ihc","ordering_info":"Order via pathology lab IHC panel. Requires FFPE tissue."}],"top_priority":{"test_name":"HRD Score (MyChoice CDx or tissue-based NGS)","priority":1,"turnaround_days":10,"cost_estimate":"$4,000-$6,000 (typically covered by insurance for Stage III/IV ovarian)","impact_if_positive":"HRD â‰¥42 â†’ PARP maintenance eligible (NCCN Category 1). Unlock mechanism map DDR chip.","impact_if_negative":"HRD <42 â†’ PARP reduced benefit. Consider ATR/CHK1 combo or platinum-only.","rationale":"HRD score determines PARP inhibitor eligibility and confidence level.","urgency":"high","test_type":"tissue","ordering_info":"Order via Myriad Genetics (MyChoice CDx) or comprehensive tumor NGS."},"total_tests":3,"high_priority_count":2,"checklist_markdown":"## ðŸ“‹ NGS Fast-Track Checklist\n\n### Priority 1: HRD Score\n- **Test**: HRD Score (MyChoice CDx or tissue-based NGS)\n- **Turnaround**: 10 days\n- **Cost**: $4,000-$6,000 (typically covered by insurance for Stage III/IV ovarian)\n- **Urgency**: HIGH\n\n**What This Unlocks**:\n- âœ… If Positive: HRD â‰¥42 â†’ PARP maintenance eligible (NCCN Category 1). Unlock mechanism map DDR chip....\n- âš ï¸ If Negative: HRD <42 â†’ PARP reduced benefit. Consider ATR/CHK1 combo or platinum-only....\n\n**Why**: HRD score determines PARP inhibitor eligibility and confidence level....\n\n**Ordering**: Order via Myriad Genetics (MyChoice CDx) or comprehensive tumor NGS.\n\n---\n\n### Priority 2: ctDNA Comprehensive Panel\n- **Test**: ctDNA Comprehensive Panel (Guardant360 CDx or FoundationOne Liquid CDx)\n- **Turnaround**: 7 days\n- **Cost**: $5,000-$7,000 (typically covered by insurance)\n- **Urgency**: HIGH\n\n**What This Unlocks**:\n- âœ… If Positive: MSI-High/TMBâ‰¥20 â†’ IO eligible. Somatic HRR â†’ PARP confidence 90%....\n- âš ï¸ If Negative: MSI-Stable/TMB<20 â†’ IO lower priority. No somatic HRR â†’ Standard care....\n\n**Why**: MSI/TMB unlock immunotherapy. Somatic HRR mutations enable PARP strategies....\n\n**Ordering**: Order via Guardant Health or Foundation Medicine. 2-3 tubes blood (EDTA).\n\n---\n\n### Priority 3: SLFN11 IHC\n- **Test**: SLFN11 IHC (Immunohistochemistry)\n- **Turnaround**: 5 days\n- **Cost**: $300-$500\n- **Urgency**: MEDIUM\n\n**What This Unlocks**:\n- âœ… If Positive: SLFN11+ â†’ Normal PARP sensitivity maintained....\n- âš ï¸ If Negative: SLFN11- â†’ Reduced PARP sensitivity. Consider ATR/CHK1....\n\n**Why**: SLFN11 expression correlates with PARP inhibitor response....\n\n**Ordering**: Order via pathology lab IHC panel. Requires FFPE tissue.\n\n---\n","provenance":{"version":"v1.1","policy_source":"MANAGER_ANSWERS_TO_ZO_SAE_QUESTIONS.md (P1, C6) + Resistance Prophet","manager":"SR + Zo","date":"2025-01-28","note":"Includes Resistance Prophet Integration"}},"hint_tiles":{"hint_tiles":[{"category":"next_test","title":"ðŸ“‹ Recommended Next Test","message":"Consider ordering HRD Score","reasons":["HRD score determines PARP inhibitor eligibility and confidence level....","Turnaround: 10 days","Unlocks: HRD â‰¥42 â†’ PARP maintenance eligible (NCCN Category 1). Unlock mechanism map DDR chip...."],"priority":1,"icon":"ðŸ§ª","action_link":"/ngs-fast-track","provenance":"next_test_recommender.priority_1"}],"total_tiles":1,"categories":["next_test"],"by_category":{"next_test":{"category":"next_test","title":"ðŸ“‹ Recommended Next Test","message":"Consider ordering HRD Score","reasons":["HRD score determines PARP inhibitor eligibility and confidence level....","Turnaround: 10 days","Unlocks: HRD â‰¥42 â†’ PARP maintenance eligible (NCCN Category 1). Unlock mechanism map DDR chip...."],"priority":1,"icon":"ðŸ§ª","action_link":"/ngs-fast-track","provenance":"next_test_recommender.priority_1"}},"summary_text":"## ðŸŽ¯ Recommended Actions\n\n### ðŸ§ª ðŸ“‹ Recommended Next Test\n**Consider ordering HRD Score**\n\n**Why:**\n- HRD score determines PARP inhibitor eligibility and confidence level....\n- Turnaround: 10 days\n- Unlocks: HRD â‰¥42 â†’ PARP maintenance eligible (NCCN Category 1). Unlock mechanism map DDR chip....\n","provenance":{"version":"v1.0","policy_source":"MANAGER_ANSWERS_TO_ZO_SAE_QUESTIONS.md (P5, C8)","manager":"SR","date":"2025-01-13","max_tiles":4,"tone":"suggestive","note":"Priority: Test â†’ Trials â†’ Monitor â†’ Avoid. Pre-NGS excludes 'avoid' tile."}},"mechanism_map":{"chips":[{"pathway":"DDR","burden":0.0,"color":"default","label":"Awaiting NGS","tooltip":"DNA damage repair pathway burden - requires tumor NGS to assess. High burden (â‰¥70%) indicates PARP/ATR/CHK1 eligibility.","status":"awaiting_ngs"},{"pathway":"MAPK","burden":0.0,"color":"default","label":"Awaiting NGS","tooltip":"RAS/RAF/MEK pathway burden - requires tumor NGS. High burden (â‰¥70%) indicates MEK/RAF inhibitor eligibility.","status":"awaiting_ngs"},{"pathway":"PI3K","burden":0.0,"color":"default","label":"Awaiting NGS","tooltip":"PI3K/AKT/mTOR pathway burden - requires tumor NGS. High burden (â‰¥70%) indicates PI3K/mTOR inhibitor eligibility.","status":"awaiting_ngs"},{"pathway":"VEGF","burden":0.0,"color":"default","label":"Awaiting NGS","tooltip":"Angiogenesis pathway burden - requires tumor NGS. High burden (â‰¥70%) supports bevacizumab addition.","status":"awaiting_ngs"},{"pathway":"IO","burden":0.0,"color":"default","label":"Awaiting NGS","tooltip":"Immune checkpoint pathway - requires MSI/TMB testing. MSI-High OR TMB â‰¥20 â†’ Immunotherapy eligible.","status":"awaiting_ngs"},{"pathway":"Efflux","burden":0.0,"color":"default","label":"Awaiting NGS","tooltip":"Drug efflux resistance (ABCB1) - requires tumor NGS. High expression â†’ Cross-resistance to taxanes/anthracyclines.","status":"awaiting_ngs"}],"status":"awaiting_ngs","message":"Mechanism map will be available once tumor NGS results are uploaded (7-10 days). Order HRD + ctDNA to unlock.","provenance":{"mode":"pre_ngs","policy":"All chips gray per Manager C9"}},"sae_features":{"status":"awaiting_ngs"},"resistance_alert":{"status":"awaiting_ngs"},"resistance_prediction":{"status":"insufficient_data","message":"Resistance prediction requires tumor NGS data and SAE features","required":["tumor_context","sae_features"],"note":"Once NGS available, Resistance Prophet will predict treatment failure 3-6 months early"},"summary":{"components_included":["clinical_trials","soc_recommendation","ca125_monitoring","wiwfm","resistance_prediction","next_test_recommender","hint_tiles","mechanism_map"],"ngs_status":"pending","confidence_level":"high (90-100%)","reasoning":"Confidence is high for guideline-based recommendations (trials, SOC, CA-125). Confidence is moderate for personalized predictions (WIWFM requires NGS)."},"provenance":{"orchestrator":"complete_care_v2_modular","for_patient":"AK (Stage IVB ovarian cancer)","endpoints_called":["clinical_trials","soc_recommendation","ca125_monitoring","wiwfm","resistance_prediction","next_test_recommender","hint_tiles","mechanism_map"],"ngs_status":"pending","generated_at":"2026-01-31T03:17:49.133029","run_id":"complete_care_v2_1769847469","note":"This is NOT a demo. Real clinical decision support for Ayesha's life.","sae_phase1_enabled":true,"sae_services":["next_test_recommender","hint_tiles","mechanism_map"],"resistance_prophet_enabled":true,"resistance_prophet_phase":"phase1_retrospective_no_ca125","manager_policy_sae":"MANAGER_ANSWERS_TO_ZO_SAE_QUESTIONS.md (Jan 13, 2025)","manager_policy_prophet":"MANAGER_ANSWERS_TO_RESISTANCE_PROPHET_QUESTIONS.md (Jan 14, 2025)","architecture":"modular_service_based"}}